Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Jefferson Award Honors Doctor Determined To Cure Rare Disease HIBM
A Los Angeles doctor who has made it his life"s work to find a cure for the rare disease Heredity Inclusion Body Myopathy, or HIBM, has won
generic viagra online
Number Of Abortion Procedures Continues To Decline In Minnesota And Wisconsin
The following summarizes news coverage of state abortion statistics in Minnesota and Wisconsin.~ Minnesota: The number of abortions performed in Minnesota decreased for the second consecutive year in 2008, according to an annual report from the state Department of Health, the Minneapolis Star Tribune reports. Except for a one-time increase in 2006, the number of abortions in Minnesota has trended downward since a peak in 1980, when 19,028 procedures were performed. The new report found that 12,948 abortions were performed in the state in 2008, a decrease of 895 from 2007. Women ages 20 to 24 accounted for about one-third of the procedures, the most among any age group. The number of procedures among teenagers continued a decline that began in the 1990s but had leveled off slightly earlier this decade, the report found. The report also found that less than one-third of women reported using contraception and about one in seven was married at the time of conception (Von Sternberg, Minneapolis Star Tribune, 7/1).~ Wisconsin: Wisconsin abortion providers performed 8,229 procedures in 2008, the lowest number since the state began collecting statistics in 1974, according to an annual report by the state Department of Health Services, the AP/Milwaukee Journal-Sentinel reports. The number of abortions has declined annually since 2003, when 10,557 procedures were performed. State law requires abortion providers to provide DHS with the data. According to the report, slightly more than half of abortions took place in the first eight weeks of pregnancy. Women who had never been married accounted for about three-fourths of all procedures. The report found that 12% of abortions occurred among women ages 35 and older; 34% were among women ages 20 to 24; 11% were among women ages 18 and 19; and 6% were among girls ages 15 to 17. The number of abortions among minors decreased from 551 in 2007 to 500 in 2008, with parents providing consent in 452 of those cases (Richmond, AP/Milwaukee Journal-Sentinel, 6/30).
plastic surgery before after
News of the day
Identification Of Brain Difference In Psychopaths
Professor Declan Murphy and colleagues Dr Michael Craig and Dr Marco Catani from the Institute of Psychiatry at King"s College London have found differences in the brain which may provide a biological explanation for psychopathy. The results of their study are outlined in the paper "Altered connections on the road to psychopathy", published in Molecular Psychiatry.
Cardiovascular

GlaxoSmithKline And Genmab Announce Top-line Results For Ofatumumab In Rheumatoid Arthritis

GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced preliminary top-line results from a Phase III study of ofatumumab administered intravenously for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to methotrexate. The study met the primary endpoint, ACR20 at 24 weeks, which indicates a 20 percent or greater improvement in the number of swollen and tender joints, as well as improvements in other disease-activity measures. In the study, 260 patients were treated and included in the analysis. At week 24, the ACR20 response rate was significantly greater for RA patients on ofatumumab (n=129) than on placebo (n=131) with a 50 percent response rate in the patients receiving ofatumumab, compared to 27 percent for patients on placebo (p-value less than 0.001). All key secondary endpoints were significant (p-value less than or equal to 0.001) There were no unexpected safety findings. The most common adverse events in the ofatumumab treated patients (greater than 5 percent) were rash, urticaria, nasopharyngitis, pruritus, throat irritation and hypersensitivity. Other than nasopharyngitis, these events generally occurred within 24 hours of the first infusion. One death, judged by the investigator as unrelated to ofatumumab, was reported in the study during the 24-week study period. "We have always believed in ofatumumab"s potential to make a difference in patients" lives. We are pleased with the results of this study, supporting the further investigation of this antibody"s promise in the treatment of RA" said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "RA can be a highly debilitating disease. It is encouraging to see the reduction in disease symptoms achieved with intravenous ofatumumab, and we look forward to presenting the full study results, " said Carlo Russo, M.D., Senior Vice President, Biopharm Development, GSK. About the study In this 24 week double-blind study, patients with active RA were randomized to receive two 700 mg doses of intravenous ofatumumab or placebo two weeks apart in addition to background methotrexate. Disease status was measured every 4 weeks. Patients for this non-IND study were recruited from Europe, South America and Australia. The primary objective of the study was to determine the efficacy of intravenous ofatumumab in reducing the clinical signs and symptoms in RA patients after two 700 mg doses of ofatumumab compared to placebo. The primary endpoint of the study was ACR20 at 24 weeks. Other key secondary objectives included safety, patient reported outcomes, biomarkers and ACR 50 and ACR 70. ACR Response The ACR 20 response is defined as a 20 percent or greater improvement from baseline in tender and swollen joint counts, and 20 percent or greater improvement in 3 of the 5 following assessments: patient and physician global assessments, pain, disability, and an acute phase reactant (ESR or CRP). About ofatumumab Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells. This epitope is different from the binding sites targeted by other CD20 antibodies currently available. Ofatumumab is being developed for other indications under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country. About GlaxoSmithKline (GSK) GlaxoSmithKline one of the world"s leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. GSK"s BioPharm R&D division has a rich early pipeline based on cutting edge molecular biology and genetic technology and a mature late-stage portfolio that will provide important medicines to oncology. GlaxoSmithKline


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009